Jack Allen: Yes, that’s great color. I actually do have a brief follow-up around enrollment. How are you thinking about enrollment in these studies in any inter patient staggers I know your competitor has recently announced that they’re extending a lower dose cohort and they’re allowed to dose concurrence. At what point do you think you could get to concurrent dosing? And what’s the current stagger between patients are now?
Kamran Alam: The current staggers 42 days and an IDMC meeting before you can proceed to the next patient. I think that it’s a bit of a of an art and a science. I think it’s — when you have enough data that you can make a request to remove the stagger, I think for us, a good we took the three patients’ worth of data and said we think based on this data, we’ve demonstrated safety, preliminary efficacy. And based on the preclinical data, there’s a rationale to go to a higher dose and we’re able to do that. So instead of dosing 3 low-dose patients in the adult study we were able to do two patients and then move to the higher dose, which we think is going to be more informative to the overall program and potentially better for patients.
So if you apply that logic, there would be a point in time where we would be comfortable potentially going to the IDMC and talking about removing the stagger and that’s just something we’ll have to do when we feel that we’ve got data that we feel sufficient to support that request in an incredible manner.
Jack Allen: Got it. Great thanks so much for the color and congratulations again on the progress.
Kamran Alam: Thanks, Jack.
Operator: We have time for one last question. Our last question comes from the line of Silvan Tuerkcan with Citizens JMP. Please proceed with your question.
Silvan Tuerkcan: Yes, thank you. Congrats on the great update. And thank you for taking my question. I just — I have a question about your dose roughly going ahead, you can double the dose faster than you expected. Can you just talk about what that means in the — in terms of the efficacy results that you’re hoping for? Do you think there could be a greater increase? Or what is your hope for the higher dose here?
Sean Nolan: I’ll start and ask Suku to chime as well. But first of all, when you look at the preclinical data, there is a dose response. So you would expect there to be a greater response moving to the higher dose. What’s driving that? You anticipate that by giving roughly more dose that you’d be transducing more cells, you’d be generating more MECP2 in the cells that need more MECP too and that overall, you should have a more significant clinical effect than what was seen in the low dose. Anything else?
Silvan Tuerkcan: Great. Thank you. Yes, if I may have a quick…
Operator: That is all the time we have for questions. I would like to hand it back to management for closing remarks.
Sean Nolan: Okay. I just want to thank everyone for taking the time, and I appreciate you listening to the story and we’re eager to continue to progress in 2024 and generate additional data and hopefully more value-creating milestones for the investors and care for the patients. So thank you, and have a good night.
Operator: Ladies and gentlemen, this does conclude today’s teleconference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.
